At Amgen, our mission is to serve patients. As a science-based, patient-focused organisation, we discover and develop innovative therapies to treat serious illnesses. Our medicines have made a significant difference in the lives of millions.
Amgen is committed to patient safety and continually monitors the safety and quality of our products. If you want to contact Amgen for any of the following reasons, please call us on +44 (0)1223 436441 (UK and Ireland), Freephone: 1800 535160 (Ireland) and provide us with the details:
If you do have any side effects, talk to your healthcare professional. This includes any possible side effects not listed in the package leaflet.
If you are in the UK (England, Scotland, Wales and Northern Ireland), you can also report adverse events or product defects directly to the Medicines and Healthcare products Regulatory Agency (MHRA).
If you are in Ireland, you may also report adverse events or product defects to the Health Products Regulatory Authority (HPRA) where you can also find reporting forms and information.
To read more about the Falsified Medicines Directive and the impact this may have on Amgen packaging, click here.
By reporting side effects, you can help provide more information on the safety of our medicines.
Below you will find information on Amgen’s product portfolio. Summary of Product Characteristics and patient information leaflets for each product can be accessed via the links. These links direct you to the Electronic Medicines Compendium (eMC) and Medicines.ie websites; and provide information about all medicines available in Great Britain, Northern Ireland, and Ireland respectively.
Please note that this information is specific to Great Britain, Northern Ireland and Ireland. Click here to read our Terms and Conditions of Sale.
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
AMGEVITA® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
AMGEVITA® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
AMGEVITA® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Aranesp® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Aranesp® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Aranesp® - Ireland Summary of Product Characteristics and Patient Information Leaflet
BEKEMVTM - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Blincyto® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Blincyto® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Blincyto® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Imlygic® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Imlygic® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Imlygic® - Ireland Summary of Product Characteristics and Patient Information Leaflet
KANJINTI® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
KANJINTI® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
KANJINTI® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Kyprolis® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Kyprolis® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Kyprolis® - Ireland Summary of Product Characteristics and Patient Information Leaflet
LUMYKRASTM - Great Britain Summary of Product Characteristics and Patient Information Leaflet
LUMYKRASTM - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Mimpara® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Mimpara® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Mimpara® - Ireland Summary of Product Characteristics and Patient Information Leaflet
NEUPOGEN® - UK Summary of Product Characteristics and Patient Information Leaflet
NEUPOGEN® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Neulasta® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Neulasta® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Neulasta® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Nplate® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Nplate® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Nplate® - Ireland Summary of Product Characteristics and Patient Information Leaflet
OTEZLA® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
OTEZLA® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
OTEZLA® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Parsabiv® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Parsabiv® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Parsabiv® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Prolia® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Prolia® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Prolia® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Repatha® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Repatha® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Repatha® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Vectibix® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
Vectibix® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
Vectibix® - Ireland Summary of Product Characteristics and Patient Information Leaflet
XGEVA® - Great Britain Summary of Product Characteristics and Patient Information Leaflet
XGEVA® - Northern Ireland Summary of Product Characteristics and Patient Information Leaflet
XGEVA® - Ireland Summary of Product Characteristics and Patient Information Leaflet
Total of 18 Products
Amgen is committed to patient safety and continually monitors the safety and quality of our products. Adverse events and product quality issues should be reported.
▼This product is subject to additional monitoring, which will allow quick identification of new safety information. You can help by reporting any side effects you may get by using the links below.
For the UK - reporting forms and information can be found at http://yellowcard.mhra.gov.uk/
For Ireland - reporting forms and information can be found at http://www.hpra.ie/
Adverse events and product quality issues should also be reported to Amgen. To report a potential adverse event or quality issue with an Amgen product, or for medical information enquiries, please call +44 (0) 1223 436441 (UK and Ireland) or Freephone: 1800 535160 (Ireland).
Job Code: IRL-NP-0124-80002
Date of preparation: January 2024